Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world to treat a patient using Elekta Evo, an ...

Beckley Psytech has announced positive topline results from its phase 2a study of ELE-101, a synthetic intravenous (IV) ...

MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative ...

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor, to assess its safety ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial for paediatric patients with cerebral adrenoleukodystrophy (cALD). The ...

The competition to gain approval for the first oral GLP-1R drug for obesity is heating up, with four phase 3 trials currently in progress, according to GlobalData. Obesity, defined as an excessive ...

Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...

Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB 001 at the 66th American Society of Hematology (ASH) Annual Meeting. The study showed that all doses of POLB 001 significantly ...

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and is now available through the NHS.